alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>

This schedule contains summary financial information extracted from the
financial statements of Realmark Property Investors Limited Partnership II for
the year ended December 31, 1999, and is qualified in its entirety by reference
to such financial statements.


</LEGEND>

<CIK>                           0000704165
<NAME>                          REALMARK PROPERTY INVESTORS LTD PARTNERSHIP II
<MULTIPLIER>                    1



<S>                                    <C>
<PERIOD-TYPE>                          12-MOS
<FISCAL-YEAR-END>                                  DEC-31-1999
<PERIOD-START>                                     JAN-01-1999
<PERIOD-END>                                       DEC-31-1999
<CASH>                                                        141,101
<SECURITIES>                                                        0
<RECEIVABLES>                                                 290,767
<ALLOWANCES>                                                  153,941
<INVENTORY>                                                         0
<CURRENT-ASSETS>                                              349,663
<PP&E>                                                     10,450,960
<DEPRECIATION>                                              5,867,469
<TOTAL-ASSETS>                                              5,039,970
<CURRENT-LIABILITIES>                                         993,556
<BONDS>                                                             0
<COMMON>                                                            0
<PREFERRED-MANDATORY>                                               0
<PREFERRED>                                                         0
<OTHER-SE>                                                          0
<TOTAL-LIABILITY-AND-EQUITY>                                5,039,970
<SALES>                                                             0
<TOTAL-REVENUES>                                            2,128,520
<CGS>                                                               0
<TOTAL-COSTS>                                               2,826,535
<OTHER-EXPENSES>                                                    0
<LOSS-PROVISION>                                                    0
<INTEREST-EXPENSE>                                            709,493
<INCOME-PRETAX>                                             (521,451)
<INCOME-TAX>                                                        0
<INCOME-CONTINUING>                                                 0
<DISCONTINUED>                                                      0
<EXTRAORDINARY>                                                     0
<CHANGES>                                                           0
<NET-INCOME>                                                (521,451)
<EPS-BASIC>                                                   (50.58)
<EPS-DILUTED>                                                       0



</TABLE>
<PAGE>   1
                                                                    EXHIBIT 23.1



INDEPENDENT AUDITORS' CONSENT

We consent to the incorporation by reference in Registration Statement Nos.
33-93538, 33-41453, 33-48646, 33-77080 and 333-4620 on Forms S-8 and 33-60260
on Form S-3 of Somanetics Corporation of our report dated January 24, 1997
(which expresses an unqualified opinion and includes an explanatory paragraph
relating to an uncertainty concerning the Company's ability to continue as a
going concern), appearing in the Annual Report on Form 10-K of Somanetics
Corporation for the year ended November 30, 1996.



/S/DELOITTE & TOUCHE LLP
------------------------
DELOITTE & TOUCHE LLP



Detroit, Michigan
February 3, 1997
HomeOffice of the SpokespersonPress Releases...Deputy Secretary Sherman’s Meeting with UK Parliamentary Under Secretary of State Rutley

# 									Deputy Secretary Sherman’s Meeting with UK Parliamentary Under Secretary of State Rutley							

Readout

Office of the Spokesperson

February 8, 2023

The following is attributable to Spokesperson Ned Price:

Deputy Secretary of State Wendy Sherman met with UK Parliamentary Under Secretary of State (Minister for Americas and Caribbean) David Rutley today in Washington, D.C.  The Deputy Secretary and Minister Rutley affirmed their countries’ enduring commitment to Ukraine’s defense.  They also discussed the importance of the UK and the EU reaching a resolution on the implementation of the Northern Ireland Protocol.  The Deputy Secretary welcomed the UK government’s commitment to resolving this issue and protecting the gains of the Belfast/Good Friday Agreement.  The Deputy Secretary and Minister Rutley also affirmed their continued cooperation in the face of challenges posed by the People’s Republic of China.

Tags

Bureau of European and Eurasian AffairsChinaDefenseDeputy Secretary of StateIrelandOffice of the SpokespersonUkraineUnited Kingdom

Back to Top
§ 405.212 Medicare Coverage IDE study criteria. ( a ) For Medicare coverage of items and services described in § 405.211, a Category A (Experimental) or Category B (Nonexperimental/investigational) IDE study must meet all of the following criteria: ( 1 ) The principal purpose of the study is to test whether the device improves health outcomes of appropriately selected patients.
( 2 ) The rationale for the study is well supported by available scientific and medical information, or it is intended to clarify or establish the health outcomes of interventions already in common clinical use.
( 3 ) The study results are not anticipated to unjustifiably duplicate existing knowledge.
( 4 ) The study design is methodologically appropriate and the anticipated number of enrolled subjects is adequate to confidently answer the research question(s) being asked in the study.
( 5 ) The study is sponsored by an organization or individual capable of successfully completing the study.
( 6 ) The study is in compliance with all applicable Federal regulations concerning the protection of human subjects found at 21 CFR parts 50, 56, and 812 and 45 CFR part 46.
( 7 ) Where appropriate, the study is not designed to exclusively test toxicity or disease pathophysiology in healthy individuals. Studies of all medical technologies measuring therapeutic outcomes as one of the objectives may be exempt from this criterion only if the disease or condition being studied is life threatening and the patient has no other viable treatment options.
( 8 ) The study is registered with the National Institutes of Health's National Library of Medicine's ClinicalTrials.gov.
( 9 ) The study protocol describes the method and timing of release of results on all pre-specified outcomes, including release of negative outcomes and that the release should be hastened if the study is terminated early.
( 10 ) The study protocol must describe how Medicare beneficiaries may be affected by the device under investigation, and how the study results are or are not expected to be generalizable to the Medicare beneficiary population. Generalizability to populations eligible for Medicare due to age, disability, or other eligibility status must be explicitly described.
( b ) [Reserved]
[78 FR 74809, Dec. 10, 2013]
#### Ernest FRIERSON v. Robert E. COX et al.

No. 52030.

Supreme Court of Mississippi.

Aug. 13, 1980.

Edward Blackmon, Jr., Blackmon, Smith & Nichols, Canton, for appellant.

John W. Christopher, Canton, for appel-lees,

Appeal from Chancery Court, Madison County; E. G. Cortright, Chancellor.

Before ROBERTSON, P. J., and WALKER and BOWLING, JJ.

AFFIRMED.
§ 412.85 Payment adjustment for certain clinical trial and expanded access use immunotherapy cases. ( a ) *General rule.* For discharges occurring on or after October 1, 2020, the amount of payment for a discharge described in paragraph (b) of this section is adjusted as described in paragraph (c) of this section.
( b ) *Discharges subject to payment adjustment.* Payment is adjusted in accordance with paragraph (c) of this section for discharges assigned to MS-DRG 018 involving expanded access use of immunotherapy, or that are part of an applicable clinical trial as determined by CMS based on the reporting of a diagnosis code indicating the encounter is part of a clinical research program on the claim for the discharge.
( c ) *Adjustment.* The DRG weighting factor determined under § 412.60(b) is adjusted by a factor that reflects the average cost for cases to be assigned to MS-DRG 018 that involve expanded access use of immunotherapy, or are part of an applicable clinical trial, to the average cost for cases to be assigned to MS-DRG 018 that do not involve expanded access use of immunotherapy and are not part of an applicable clinical trial.
[85 FR 59020, Sept. 18, 2020]
[Federal Register Volume 74, Number 170 (Thursday, September 3, 2009)]
[Notices]
[Pages 45610-45611]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: E9-21320]


-----------------------------------------------------------------------

DEPARTMENT OF COMMERCE

International Trade Administration

[A-533-838]


Carbazole Violet Pigment 23 From India: Extension of Time Limit 
for Preliminary Results of Antidumping Duty Administrative Review

AGENCY: Import Administration, International Trade Administration, 
Department of Commerce.

FOR FURTHER INFORMATION CONTACT: Jerrold Freeman or Richard Rimlinger, 
AD/CVD Operations, Office 5, Import Administration, International Trade 
Administration, U.S. Department of Commerce, 14th Street and 
Constitution Avenue, NW., Washington, DC, 20230; telephone: (202) 482-
0180 or (202) 482-4477, respectively.

SUPPLEMENTARY INFORMATION:

Background

    At the request of interested parties, the Department of Commerce 
(the Department) initiated an administrative review of the antidumping 
duty order on carbazole violet pigment 23 from India for the period 
December 1, 2007, through November 30, 2008. See Initiation of 
Antidumping and Countervailing Duty Administrative Reviews and Requests 
for Revocation in Part, 74 FR 5821 (February 2, 2009).

Extension of Time Limit for Preliminary Results

    Section 751(a)(3)(A) of the Tariff Act of 1930, as amended (the 
Act), requires the Department to make a preliminary determination 
within 245 days after the last day of the anniversary month of an

[[Page 45611]]

order for which a review is requested and a final determination within 
120 days after the date on which the preliminary determination is 
published. If it is not practicable to complete the review within these 
time periods, section 751(a)(3)(A) of the Act allows the Department to 
extend the time limit for the preliminary determination to a maximum of 
365 days after the last day of the anniversary month. See also 19 CFR 
351.213(h)(2).
    We determine that it is not practicable to complete the preliminary 
results of this administrative review by the current deadline of 
September 2, 2009, for several reasons. Specifically, the Department 
has granted the respondent several extensions to respond to the 
original and supplemental questionnaires. Accordingly, the Department 
needs additional time to review and analyze the responses submitted by 
the respondent. Further, the Department requires additional time to 
conduct verification. Therefore, in accordance with section 
751(a)(3)(A) of the Act and 19 CFR 351.213(h)(2), we are extending the 
time period for issuing the preliminary results of these reviews for 75 
days until November 16, 2009. The final results continue to be due 120 
days after the publication of the preliminary results.
    This notice is published in accordance with sections 751(a)(3)(A) 
and 777(i)(1) of the Act and 19 CFR 351.213(h)(2).

    Dated: August 27, 2009.
John M. Andersen,
Acting Deputy Assistant Secretary for Antidumping and Countervailing 
Duty Operations.
[FR Doc. E9-21320 Filed 9-2-09; 8:45 am]
BILLING CODE 3510-DS-P
#### The DELTA NATIONAL BANK OF YAZOO CITY v. M. G. HOLDER.

No. 80-C-2527.

Supreme Court of Louisiana.

Nov. 21, 1980.

In re The Delta National Bank of Yazoo City, applying for writs of certiorari, review, and mandamus. Parish of St. Charles. No. 21824.

Writ granted.
Editorial Note on Part 414
Editorial Note: Nomenclature changes to part 414 appear at 60 FR 50442, Sept. 29, 1995, and 60 FR 53877, Oct. 18, 1995.

§ 414.1660 Continuity of pricing when HCPCS codes are divided or combined. ( a ) *General rule.* If HCPCS codes for lymphedema compression treatment items are divided or combined, the payment amounts for the old codes are mapped to the new codes to ensure continuity of pricing.
( b ) *Mapping of payment amounts.* ( 1 ) If there is a single code that describes two or more distinct complete items (for example, two different but related or similar items), and separate codes are subsequently established for each item, then the payment amounts that applied to the single code continue to apply to each of the items described by the new codes.
( 2 ) If the codes for several different items are combined into a single code, then the payment amounts for the new code are established using the average (arithmetic mean), weighted by allowed services, of the payment amounts for the formerly separate codes.
No. 99-467.

#### Trice *v.*Board of Trustees for Okolona Municipal Separate School District et al.

C. A. 5th Cir. Cer-tiorari denied.
<TABLE> <S> <C>

<ARTICLE>                     5
<MULTIPLIER>                  1                 
<CURRENCY>                    U.S. DOLLARS
       
<S>                             <C>
<PERIOD-TYPE>                 3-MOS
<FISCAL-YEAR-END>             DEC-31-1997
<PERIOD-START>                APR-01-1997                 
<PERIOD-END>                  JUN-30-1997
<EXCHANGE-RATE>               1
<CASH>                            442,213
<SECURITIES>                            0
<RECEIVABLES>                     591,581
<ALLOWANCES>                       15,000
<INVENTORY>                     1,110,318
<CURRENT-ASSETS>                2,411,410
<PP&E>                          1,862,962
<DEPRECIATION>                    713,538
<TOTAL-ASSETS>                  3,602,086
<CURRENT-LIABILITIES>             557,059
<BONDS>                                 0 
<PREFERRED-MANDATORY>                   0
<PREFERRED>                             0
<COMMON>                           16,366
<OTHER-SE>                      2,081,918 
<TOTAL-LIABILITY-AND-EQUITY>    3,602,086
<SALES>                         1,227,978
<TOTAL-REVENUES>                1,227,978
<CGS>                             564,705
<TOTAL-COSTS>                     564,705
<OTHER-EXPENSES>                  560,639
<LOSS-PROVISION>                        0
<INTEREST-EXPENSE>                 27,487
<INCOME-PRETAX>                    90,049
<INCOME-TAX>                            0 
<INCOME-CONTINUING>                90,049
<DISCONTINUED>                          0
<EXTRAORDINARY>                         0 
<CHANGES>                               0
<NET-INCOME>                       90,049   
<EPS-PRIMARY>                        0.06
<EPS-DILUTED>                        0.06
        


</TABLE>
Exhibit 99.1

              CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,
                     AS ADOPTED PURSUANT TO SECTION 906
                      OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q of Merchants
Bancshares, Inc. (the "Company") for the period ending September 30, 2002,
as filed with the Securities and Exchange Commission on the date hereof
(the "Report"), I, Joseph L. Boutin, President and Chief Executive Officer
of the Company, certify, pursuant to 18 U.S.C. [SECTION]1350, as adopted
pursuant to [SECTION]906 of the Sarbanes-Oxley Act of 2002, that, to the best
of my knowledge: (1) the Report fully complies with the requirements of
Section 13(a) or 15(d) of the Securities Exchange Act of 1934, and (2) the
information contained in the Report fairly presents, in all material
respects, the financial condition and the results of operations of the
Company.


                                       Merchants Bancshares, Inc.

                                       By: /s/ Joseph L. Boutin
                                           --------------------
                                           Joseph L. Boutin
                                           President and Chief Executive
                                           Officer

                                           November 14, 2002
                                           -----------------
                                           Date


<PAGE>
# Ethiopia

298 items

        -    Media Note  		Special Envoy for the Horn of Africa Hammer Travels to Uganda and Ethiopia	  January 17, 2024 
        -    Press Statement  		23rd Anniversary of the Algiers Agreement between the Governments of Ethiopia and Eritrea	  Matthew MillerDecember 12, 2023 
        -    Media Note  		Special Envoy for the Horn of Africa Hammer Travels to Djibouti, Qatar, and Ethiopia	  December 7, 2023 
        -    Report  		Country Reports on Terrorism 2022: Ethiopia	  November 29, 2023 
        -    Bilateral Relations Fact Sheet  		U.S. Relations With Ethiopia	  November 20, 2023 
        -    Readout  		Secretary Blinken’s Call with Ethiopian Prime Minister Abiy	  November 17, 2023 
        -    Press Statement  		1st Anniversary of Ethiopia’s Cessation of Hostilities Agreement	  Antony J. BlinkenNovember 2, 2023 
        -    Remarks  		Ethiopia: One Year after the Pretoria Agreement	  Beth Van SchaackOctober 31, 2023Open SocietyWashington, D.C. 
        -    Press Statement  		Troika Welcomes Meeting of Sudanese Civilians in Addis Ababa to Chart Next Steps in Restoring Sudan’s Democratic Governance	  Matthew MillerOctober 26, 2023 
        -    Overseas Schools Fact Sheet  		Addis Ababa, Ethiopia: International Community School of Addis Ababa: 2023-2024 Fact Sheet	  October 4, 2023 

previous page12345…30next page

Back to Top
Exhibit 23.1

           CONSENT OF ERNST & YOUNG LLP, INDEPENDENT REGISTERED PUBLIC
                                ACCOUNTING FIRM

We consent to the  incorporation  by reference in this Annual Report (Form 10-K)
of Omega Financial Corporation of our reports dated March 15, 2006, with respect
to the consolidated financial statements of Omega Financial  Corporation,  Omega
Financial Corporation  management's  assessment of the effectiveness of internal
control over financial reporting, and the effectiveness of internal control over
financial reporting of Omega Financial Corporation,  included in the 2005 Annual
Report to Shareholders of Omega Financial Corporation.

We consent to the  incorporation  by  reference  in the  following  Registration
Statements:

      1.    Registration  Statement  (Form S-8 No.  33-15780)  pertaining to the
            Employee Stock Purchase Plan and the 1986 Stock Option Plan,

      2.    Registration  Statement  (Form S-8 No.  33-82214)  pertaining to the
            Employee  Stock  Purchase  Plan,  the 1986 Stock Option Plan and the
            1994 Stock Option Plan for Non-Employee Directors,

      3.    Registration  Statement (Form S-8 No. 333-100931)  pertaining to the
            1994 Stock Option Plan for Non-Employee Directors,

      4.    Registration  Statement (Form S-8 No. 333-113849)  pertaining to the
            (1986) Stock Option Plan, the Employee Stock Purchase Plan, the 1994
            Stock Option Plan for Non-Employee Directors,  the 1996 Stock Option
            Plan and the 2004 Stock Option Plan for Non-Employee Directors, and

      5.    Registration  Statement (Form S-8 No. 333-124596)  pertaining to the
            Employee  Stock  Purchase  Plan and the 2004 Stock  Option  Plan for
            Non-Employee Directors of Omega Financial Corporation,

of our reports dated March 15, 2006, with respect to the consolidated  financial
statements  of  Omega  Financial   Corporation,   Omega  Financial   Corporation
management's  assessment of the effectiveness of internal control over financial
reporting, and the effectiveness of internal control over financial reporting of
Omega  Financial  Corporation,  incorporated  by reference in the Annual  Report
(Form 10-K) for the year ended December 31, 2005.


/s/ Ernst & Young LLP

Pittsburgh, Pennsylvania
March 15, 2006


                                       49
EXHIBIT 32.2


Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C.§ 1350)
  The undersigned, as the chief financial officer of PAB Bankshares, Inc., certifies, to the best of my knowledge, that the Annual Report on Form 10-K for the period ended December 31, 2009, which accompanies this certification fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934 and the information contained in the periodic report fairly presents, in all material respects, the financial condition and results of operations of PAB Bankshares, Inc. at the dates and for the periods indicated.  The foregoing certification is made pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350) and shall not be relied upon for any other purpose.
 
 Dated this 9th day of March, 2010.
  
 /s/ Nicole S. StokesNicole S. StokesExecutive Vice President and Chief Financial Officer
 
 
 A signed original of this written statement required by Section 906 has been provided to PAB Bankshares, Inc. and will be retained by PAB Bankshares, Inc. and furnished to the SEC or its staff upon request.
HomeSlovakia

# Slovakia

87 items

        -    Depositary Actions - Treaty Affairs  		North Macedonia Protocol – Notification of Deposit of Instrument; Montenegro, Slovakia and Croatia, May 23, 2019	   
        -    Report  		Slovakia	  June 21, 2019 
        -    Report  		Slovakia	  June 20, 2019 
        -    		Slovakia	  April 25, 2019 
        -    Report  		Slovakia	  March 13, 2019 
        -    Report  		Slovak Republic	  July 19, 2018 
        -    TIAS  		Slovak Republic (18-712) – Protocol Amending and Extending Agreement of November 8, 2007 for Scientific and Technological Cooperation	  July 12, 2018 
        -    Report  		Slovakia	  June 28, 2018 
        -    Report  		Slovak Republic	  May 29, 2018 
        -    Report  		Slovakia	  April 20, 2018 

previous page1…56789next page

Back to Top
# C_2005330EN.01002103.xml

| 24.12.2005 | EN | Official Journal of the European Union | C 330/21 |
| --- | --- | --- | --- |

24.12.2005

EN

Official Journal of the European Union

C 330/21

---

Judgment of the Court of First Instance of 25 October 2005 — Cwik v Commission

(Case T-96/04) (1)

1

(Officials - Evaluation exercise 2001/2002 - Career development report - Application for annulment - Plea of illegality - Manifest errors of assessment - Errors of fact - Psychological harassment - Compensation for damage suffered - Non-material damage)

(2005/C 330/53)

Language of the case: French

Parties

Applicant(s): Michael Cwik (Tervuren, Belgium) (represented by: N. Lhoëst and E. de Schietere de Lophem, lawyers)

Applicant(s):

Defendant(s): Commission of the European Communities (represented by: L. Lozano Palacios and H. Krämer, Agents)

Defendant(s):

Application for

Annulment of the decision of the Commission confirming the applicant's career development report for the period from 1 July 2001 to 31 December 2002 and payment of symbolic damages for the non-material damage alleged

Operative part of the judgment

The Court:

| 1) | Dismisses the application; |
| --- | --- |

1)

Dismisses the application;

| 2) | Orders each party to bear its own costs. |
| --- | --- |

2)

Orders each party to bear its own costs.

---

(1)  OJ C 106, 30.4.2004.

1

---